# Efficacy and Safety Evaluating Study to Compare Kanarb (Fimasartan) and Cozaar® (Losartan) in Adult Patients With Grade I-II Arterial Hypertension

Study · id `cardio:ct-nct02248961` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02248961](<https://clinicaltrials.gov/study/NCT02248961>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02248961

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 179 participants.

## Technical summary

Registry record NCT02248961. Randomized; no masking; primary purpose treatment. Start 2014-05 (registry gives no type); primary completion 2015-08 (actual). Results posted on 2019-05-06.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 179 participants (enrolled count; ClinicalTrials.gov record NCT02248961, source copy `cardio:ctgov-nct02248961-2019-05-06`, retrieved 2026-10-26)
- Start date: 2014-05 (registry gives no type) (ClinicalTrials.gov record NCT02248961, source copy `cardio:ctgov-nct02248961-2019-05-06`, retrieved 2026-10-26)
- Primary completion: 2015-08 (actual) (ClinicalTrials.gov record NCT02248961, source copy `cardio:ctgov-nct02248961-2019-05-06`, retrieved 2026-10-26)
- Completion: 2015-08 (actual) (ClinicalTrials.gov record NCT02248961, source copy `cardio:ctgov-nct02248961-2019-05-06`, retrieved 2026-10-26)
- Results first posted: 2019-05-06 (ClinicalTrials.gov record NCT02248961, source copy `cardio:ctgov-nct02248961-2019-05-06`, retrieved 2026-10-26)
- Countries: Russia (ClinicalTrials.gov record NCT02248961, source copy `cardio:ctgov-nct02248961-2019-05-06`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02248961-2019-05-06`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety Evaluating Study to Compare Kanarb (Fimasartan) and Cozaar® (Losartan) in Adult Patients With Grade I-II Arterial Hypertension
- Condition: Arterial Hypertension
- Intervention (Drug): Fimasartan
- Intervention (Drug): Losartan
- Lead sponsor: R-Pharm
- Lead sponsor class: INDUSTRY
- Collaborator: Covance
- Collaborator class: INDUSTRY
- Collaborator: Boryung Pharmaceutical Co., Ltd
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry intervention name matches this record: Losartan (`cardio:losartan`)
- Registry lists this organization as a collaborator: Covance (`cardio:org-covance`)
- Registry lists this organization as a collaborator: Boryung Pharmaceutical Co., Ltd (`cardio:org-boryung-pharmaceutical-co-ltd`)

## Provenance

Content hash: 063d0008ddb6e14fb8836ad99da480b695b7a6adccdc56a381702241fe67d061
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
